It is imperative to unravel prostate cancer
biology to enable the identification of key
molecular events and molecules that aid
in diagnosis, prognosis, and the discovery
of new therapeutic targets.
3
Identifying
key molecular
alterations in
prostate cancer
Improved survival benefit with increased
docetaxel cycles in prostate cancer
JAMA Oncology
The study results indicate that continuing
docetaxel chemotherapy improves clinical
benefit in patients with mCPRC, but further
prospective studies are needed to validate
these findings.
25
First-line ceritinib vs platinum-based
chemotherapy in advanced ALK-
rearranged non-small cell lung cancer
The Lancet
Ceritinib was associated with a significant
improvement compared with chemotherapy
as a first-line treatment in patients with ALK-
rearranged NSCLC.
29
Vemurafenib in metastatic melanoma
patients with brain metastases
Annals of Oncology
The results showed that melanoma
BM responded in a clinically meaningful
way to vemurafenib. This agent can be
administered without causing significant
CNS toxicity.
30
OPINION
... in the triplet
combination,
cetuximab likely
serves to counteract
feedback-loop
activation of EGFR
after BRAF blockade.
It will remain to be
seen if regulatory
agencies, guideline
committees will
see the results as
practice-changing
19
EDITOR’S PICKS
Longer-interval dosing of
zoledronic acid effective in
patients with bone metastases
7
ECCO 2017
8
Small renal mass biopsy avoids
unnecessary surgery
mpMRI for diagnosing prostate
cancer recurrence superior to
PET, CT
ASCOGI 2017
18
Simultaneous EGFR, BRAF
inhibition effective in BRAF
V600-mutated mCRC
More patients with rectal cancer
are candidates for a watch-and-
wait approach
VOL. 2 • NO. 2 • 2017
RESEARCH NEWS AND VIEWS FROM ELSEVIER
ISSN 2206-463X